ATE551062T1 - Plasmaabgereicherte nicht-hämatozyten- abgereicherte nabelschnurblutprodukte und verfahren zu ihrer verwendung - Google Patents

Plasmaabgereicherte nicht-hämatozyten- abgereicherte nabelschnurblutprodukte und verfahren zu ihrer verwendung

Info

Publication number
ATE551062T1
ATE551062T1 AT06771915T AT06771915T ATE551062T1 AT E551062 T1 ATE551062 T1 AT E551062T1 AT 06771915 T AT06771915 T AT 06771915T AT 06771915 T AT06771915 T AT 06771915T AT E551062 T1 ATE551062 T1 AT E551062T1
Authority
AT
Austria
Prior art keywords
ucb
plasma
methods
umbilical cord
cord blood
Prior art date
Application number
AT06771915T
Other languages
English (en)
Inventor
Robert Chow
Original Assignee
Stemcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37482333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE551062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stemcyte Inc filed Critical Stemcyte Inc
Application granted granted Critical
Publication of ATE551062T1 publication Critical patent/ATE551062T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
  • Environmental Sciences (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06771915T 2005-06-02 2006-06-02 Plasmaabgereicherte nicht-hämatozyten- abgereicherte nabelschnurblutprodukte und verfahren zu ihrer verwendung ATE551062T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68712705P 2005-06-02 2005-06-02
US73395605P 2005-11-03 2005-11-03
PCT/US2006/021405 WO2006130812A2 (en) 2005-06-02 2006-06-02 Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE551062T1 true ATE551062T1 (de) 2012-04-15

Family

ID=37482333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06771915T ATE551062T1 (de) 2005-06-02 2006-06-02 Plasmaabgereicherte nicht-hämatozyten- abgereicherte nabelschnurblutprodukte und verfahren zu ihrer verwendung

Country Status (11)

Country Link
EP (1) EP1906729B1 (de)
JP (1) JP2008545755A (de)
KR (1) KR20080027295A (de)
AT (1) ATE551062T1 (de)
AU (1) AU2006252363A1 (de)
BR (1) BRPI0610968A2 (de)
CA (1) CA2609266A1 (de)
IL (1) IL187641A0 (de)
MX (1) MX2007015201A (de)
RU (1) RU2007148802A (de)
WO (1) WO2006130812A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537624A (ja) * 2007-03-28 2010-12-09 サーモジェネシス コーポレーション 骨髄または臍帯血から回収した幹細胞と前駆細胞の組成物、それらを用意するためのシステムおよび方法
RU2343928C1 (ru) * 2007-04-03 2009-01-20 Открытое акционерное общество "Институт стволовых клеток человека" Способ получения ядросодержащих клеток из пуповинной крови
CN102144028B (zh) * 2008-09-03 2017-12-26 中胚有限公司 造血前体的扩增
WO2011127472A1 (en) * 2010-04-09 2011-10-13 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function
EP3590520B1 (de) * 2010-04-09 2021-12-29 Fred Hutchinson Cancer Research Center Zusammensetzungen zur bereitstellung einer hämatopoietischen funktion ohne hla-übereinstimmung
JP5899246B2 (ja) * 2011-02-18 2016-04-06 ステムサイト インコーポレーテッドＳｔｅｍｃｙｔｅ，Ｉｎｃ． 幹細胞の包装製品並びに同包装製品を作製する方法および輸送する方法
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
US20170303530A1 (en) * 2014-11-14 2017-10-26 Japanese Red Cross Society Method and solution for cryopreservation of umbilical cord blood and peripheral blood
RU2590688C2 (ru) * 2014-11-19 2016-07-10 Публичное акционерное общество "Институт Стволовых Клеток Человека" Способ получения суспензии ядросодержащих клеток из пуповинной крови со стандартизированной концентрацией
SG11201707134WA (en) * 2015-03-06 2017-10-30 Ajou Univ Industry-Academic Coop Found Cell therapeutic agent for cancer treatment and combination therapy with same
EP4017507A4 (de) * 2019-08-20 2023-09-06 Stemcyte, Inc. Behandlung von kardiovaskulären erkrankungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789147A (en) * 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US20030215942A1 (en) * 2002-02-14 2003-11-20 Stemcyte, Inc. Undesignated allogeneic stem cell bank

Also Published As

Publication number Publication date
JP2008545755A (ja) 2008-12-18
RU2007148802A (ru) 2009-07-20
BRPI0610968A2 (pt) 2019-05-14
WO2006130812A2 (en) 2006-12-07
MX2007015201A (es) 2008-03-14
KR20080027295A (ko) 2008-03-26
WO2006130812A3 (en) 2007-09-13
EP1906729A2 (de) 2008-04-09
EP1906729A4 (de) 2009-08-12
EP1906729B1 (de) 2012-03-28
IL187641A0 (en) 2008-03-20
CA2609266A1 (en) 2006-12-07
HK1124484A1 (en) 2009-07-17
AU2006252363A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
IL187641A0 (en) Umbilical cord blood compositions
Casirati et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Bassani et al. Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent anti-tumor effects
Leung Use of NK cell activity in cure by transplant
Pradier et al. Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity
Jeanpierre et al. The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission
Schulz et al. Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems
EA200802213A1 (ru) Способы лечения заболеваний крови
DE602004018788D1 (de) Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
WO2008040027A3 (en) Directed differentiation and maturation of stem cell-derived cardiomyocytes
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CN113454207A (zh) 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors
Wang et al. In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A
Weber et al. Editing a gglobin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype
Wang et al. Administration of the Resveratrol Analogues Isorhapontigenin and Heyneanol‐A Protects Mice Hematopoietic Cells against Irradiation Injuries
Saraf et al. Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers
WO2025213182A1 (en) Combinatorial approaches for targeting hematopoietic cells
Zhang et al. Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease
Kong et al. Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients
Mohammed et al. Leukapheresis cell concentration adjustment required for a successful recovery of HSC after cryopreservation
WO2007067905A3 (en) THERAPEUTIC USE FOR α1 PROTEINASE INHIBITOR IN HEMATOPOIESIS
WO2005005608A3 (en) Compositions and methods for differentiating adipose stromal cells into pancratic beta cells
Giancola et al. Evaluation of an automated closed fluid management device for processing expanded cytokine‐induced killer cells to use in immunotherapy programs for cancer
Chow et al. Unrelated cord blood transplantation (CBT) of 101 hemoglobinopathy (HGB) patients